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The DNA damage response (DDR) rapidly recognizes DNA lesions and initiates the
appropriate cellular programs to maintain genome integrity. This includes the coordination
of cell cycle checkpoints, transcription, translation, DNA repair, metabolism, and cell fate
decisions, such as apoptosis or senescence (Jackson and Bartek, 2009). DNA double-
strand breaks (DSBs) represent one of the most cytotoxic DNA lesions and defects in
their metabolism underlie many human hereditary diseases characterized by genomic
instability (Stracker and Petrini, 2011; McKinnon, 2012). Patients with hereditary defects
in the DDR display defects in development, particularly affecting the central nervous
system, the immune system and the germline, as well as aberrant metabolic regulation
and cancer predisposition. Central to the DDR to DSBs is the ataxia-telangiectasia mutated
(ATM) kinase, a master controller of signal transduction. Understanding howATM signaling
regulates various aspects of the DDR and its roles in vivo is critical for our understanding of
human disease, its diagnosis and its treatment. This review will describe the general roles
of ATM signaling and highlight some recent advances that have shed light on the diverse
roles of ATM and related proteins in human disease.
Keywords: ataxia-telangiectasia, Nijmegen breakage syndrome, AT like disease, ATM, Mre11 complex, apoptosis,
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THE DNA DAMAGE RESPONSE TO DOUBLE-STRAND BREAKS
In response to a diverse array of DNA lesions, cells mount a DNA
damage response (DDR) to maintain genome integrity (Jackson
and Bartek, 2009). Following the recognition of a DNA lesion
by a sensor protein, the DDR sets in to motion a complex net-
work of signal transduction. The DDR (Figure 1) controls cell
cycle checkpoints, regulates transcription, recruits the appropriate
DNA repair machinery to lesions, responds to metabolic require-
ments, and controls cell fate decisions, such as apoptosis and
senescence. Ultimately, the DDR will prevent genomic instabil-
ity from accumulating by preventing cells with damaged DNA
from propagating or being passed on to progeny through the
germline.
While cells must identify and respond to diverse lesions, the
DNA double-strand break (DSB) represents a particularly impor-
tant threat to genome integrity. DSBs can be generated by exposure
to ionizing radiation (IR) or various chemical compounds, such
as topoisomerase inhibitors, that interfere with DNA replication
and cell division. More pertinent to the developmental patholo-
gies of hereditary diseases arising from deﬁciencies in the DDR
are endogenous sources of DSBs. The generation of the anti-
body repertoire as well as the maturation of germ cells both
involve the programed generation and repair of DSBs via cellu-
lar enzymes (Nussenzweig and Nussenzweig, 2010; Sasaki et al.,
2010). DSBs can also arise duringDNAreplication due to exposure
to metabolites, such as reactive oxygen species (ROS), the activ-
ity of enzymes, such as topoisomerases, which break and rejoin
DNA strands, and limitations in raw material needed for replica-
tion, such as nucleotides, that can promote fragile site expression
and chromosomal breakage (Tsantoulis et al., 2008; Bester et al.,
2011). Two major pathways of DSB are utilized in the cell, non-
homologous end-joining (NHEJ), that is operative throughout the
cell cycle, and homology directed repair (HDR) that is restricted
to S/G2 when a sister chromatid is present as a template (for a
detailed overview of these repair pathways and subpathways, we
refer the reader to a recent review; Chapman et al., 2012). The
killing of cancer cells via DSB generation is amajor strategy in can-
cer treatment and the cellular responses and mechanisms of repair
and acquired resistance to these agents is important to understand
in order to improve the efﬁcacy of current treatment regimens
(Helleday et al., 2008).
DNA DOUBLE-STRAND BREAKS AND HUMAN DISEASE
The identiﬁcation of numerous human genetic instability syn-
dromes, as well as their modeling in different experimental
systems, has been invaluable to our understanding of the DDR
in human disease. Ataxia-telangiectasia (A-T, ATM mutation),
the related A-T like disease (ATLD, MRE11 mutation), Nijmegen
breakage syndrome (NBS, NBS1/NBN mutation) and the more
recently identiﬁed NBS like disease (NBSLD, RAD50 mutation),
all presentwith similar pathological outcomes inhumans (Stracker
and Petrini, 2011). Cells from these patients have increased lev-
els of chromosomal instability, are highly sensitive to DSBs, and
show defective signaling responses such as impaired checkpoint
activation or variable defects in apoptosis. Patients are partic-
ularly affected in central nervous system (CNS) development,
exhibiting either neurodegeneration or microcephaly, and dis-
play varying degrees of immunodeﬁciency (McKinnon, 2012). In
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FIGURE 1 | Schematic of the DDR to DSBs. Following DSB induction,
they are recognized by sensor proteins such as the Mre11 complex. This
leads to the activation of ATM and related kinases that promote rapid
post-translational modiﬁcations (PTMs) on many proteins and remodeling of
chromatin structure around the break sites. Effector proteins such as the
Chk1 and Chk2 kinases amplify the signal and cells can activate cell cycle
checkpoints, regulate transcription, translation, and metabolism,
and activate the appropriate DNA repair processes. In some
cellular contexts, or in the face of irreparable lesions, cells
can activate apoptosis and senescence. The collective result
is the prevention of genomic instability and the accompanying
pathological outcomes.
addition, these disorders are often characterized by cancer predis-
position and in some cases extensive problems related to fertility
and metabolism. This review will focus on ATM kinase signal-
ing and attempt to highlight recent work that has improved our
understanding of its role in human disease through the regulation
of DSB signaling and additional cellular functions that extend
beyond the DDR.
ACTIVATION OF THE ATM KINASE: A CENTRAL TRANSDUCER
OF DSB SIGNALING
ACTIVATION IN RESPONSE TO DNA DOUBLE-STRAND BREAKS
Double-strand breaks are recognized by the Mre11–Rad50–Nbs1
(MRN) or Mre11 complex, which is a sensor of DSBs. Capture
of DNA ends by the Mre11 complex leads to the rapid activation
of the ataxia-telangiectasia mutated (ATM) kinase (Stracker and
Petrini, 2011). ATM is a member of the phosphatidylinositol 3-
kinase-related kinase (PIKK) family and is the primary transducer
of DSB-induced signaling (Lempiainen and Halazonetis, 2009).
The closely related disease pathology resulting from mutations in
ATM,or any of the Mre11 complex genes, highlights their intimate
relationship inDSB signaling. However, it is also worth noting that
bothATMand theMre11 complex have central functions indepen-
dent from one another as ATM is synthetically lethal with many
hypomorphic mutations in the Mre11 complex, some of which
do not impair ATM activation (Williams et al., 2002; Theunissen
et al., 2003).
In undamaged cells,ATMexists in a dimeric ormultimeric con-
ﬁguration (Bakkenist and Kastan, 2003). Following Mre11 com-
plex sensing of DSBs, ATM undergoes autophosphorylation on at
least four residues (S367, S1893, S1981, and S2996) that promote
its monomerization and kinase activity (Figures 2A,B; Bakkenist
and Kastan, 2003; Kozlov et al., 2006, 2011). Autophosphoryla-
tion is regulated through interactions with several phosphatases
that exert opposing inﬂuences, including protein phosphatase
2A (PP2A), protein phosphatase 5 (PP5), and wild type p53-
induced phosphatase 1 (WIP1; Ali et al., 2004; Goodarzi et al.,
2004; Shreeram et al., 2006a). HumanATM-deﬁcient cells comple-
mented with S1981A, S367A, or S2996A mutants showed defective
ATM-dependent responses to DNA damage (Kozlov et al., 2011).
However, a murine allele with a triple mutation in the analogous
sites to human S367, S1889, and S1981 complemented the defects
of ATM deﬁciency in vivo, including checkpoint activity, germ
cell development, lymphocyte development, and radiosensitivity
(Daniel et al., 2008). Furthermore, autophosphorylation is not
required for the activation of ATM in several in vitro settings (Lee
and Paull, 2005; Dupre et al., 2006). The reasons for these dis-
crepancies between complementation experiments with human
and murine ATM remain unclear but may reﬂect species-speciﬁc
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FIGURE 2 | Activation of ATM and post-translational modifications.
(A) Schematic of the ATM protein with domain organization (FAT = FRAP,
ATM, andTRAP). Major autophosphorylation sites (S367, S1893, S1981,
S2996), theTIP60 acetylation site (K3016) and a critical cysteine involved
in ROS activation are shown. (B) Activation of ATM by DNA damage or
hypotonic stress requires the Mre11 complex (Mre11, Rad50, Nbs1)
or ATMIN, respectively. Activated ATM is monomeric, phosphorylated
and acetylated. Alternatively, ATM is activated directly by ROS that
oxidizes cysteine residues to promote disulﬁde bridge-mediated
dimerization.
differences or the experimental context (a recent review from the
Khanna and Lavin groups included a detailed discussion of this
issue; Bhatti et al., 2011).
The modulation of chromatin structure inﬂuences radiosensi-
tivity and it has become clear that chromatin status plays a major
role in ATM activation and the regulation of its activity at break
sites (Bakkenist and Kastan, 2003; Murga et al., 2007). Acetylation
of lysine 3016 by the TIP60 acetyltransferase is required for ATM
activation in response to DSBs (Sun et al., 2005). TIP60 activity
is dependent on activating transcription factor 2 (ATF2) and an
interaction with histone H3 lysine 9 tri-methylation (H3K9me3)
that is unmasked following the damage-induced removal of het-
erochromatin protein 1b (HP1b; Bhoumik et al., 2005; Sun et al.,
2009). The Mre11 complex is crucial for the localization of TIP60
to H3K9me3, a well-established marker of heterochromatin that
also occurs in other regions of the genome. ATF2 interacts with
TIP60 and independently controls its levels and activity prior to
damage. Dissociation of ATF2 following damage results in higher
levels and activity of TIP60 to promote ATM activation (Bhoumik
et al., 2008).
In addition to promoting ATM activation, the Mre11 com-
plex, in conjunction with mediator of DNA damage checkpoint
protein 1 (MDC1) mediator protein and the high mobility
group protein HMGN1 (high mobility group nucleosome binding
domain 1), facilitates the chromatin retention of ATM following
DSB detection. The Mre11 complex promotes the rapid load-
ing of active, phosphorylated ATM at breaks through interactions
with the C-terminus of Nbs1 (Falck et al., 2005; You et al., 2005,
2007). ATM interactions with chromatin are enhanced in cells
treated with histone deacetylase inhibitors or in cells lacking
HMGN1, arguing that chromatin topology plays a crucial role
in mediating ATM–chromatin interactions, even in the absence
of DSBs (Kim et al., 2009). Despite enhanced chromatin reten-
tion of ATM in cells lacking HMGN1, DSB-induced activation
of ATM is impaired, consistent with the proposition that ATM
interactions with chromatin prior to DNA damage govern its
activation.
POST-TRANSLATIONAL MODIFICATIONS OF ATM
The mechanism by which post-translational modiﬁcations
(PTMs) regulate ATM activation and activity remains largely
unclear. It has been proposed that autophosphorylation sites may
have cell cycle-speciﬁc roles or regulate other modiﬁcations that
are required for ATM activation (Kozlov et al., 2011). The phos-
phorylation of ATM at S794 by cyclin-dependent kinase 5 (CDK5)
in post-mitotic neurons has been reported to be required for
subsequent autophosphorylation of S1981, providing some prece-
dence for sequential regulation of ATM (Tian et al., 2009). The
N-terminus of ATM has been identiﬁed as an interaction domain
with Nbs1 and is required for chromatin retention (Falck et al.,
2005; Young et al., 2005). Different patterns of phosphorylation
in the N-terminus could modulate substrate interactions, chro-
matin binding, or subcellular localization. The damage-induced
autophosphorylation of ATM on S1981 has been demonstrated
to promote the retention of ATM to DSBs in a manner that
is dependent on the Mre11 complex and the mediator protein,
MDC1 (So et al., 2009). Collectively, existing data would sup-
port a model that auto and trans-phosphorylation could modulate
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kinase activity, protein–protein interactions, substrate speciﬁcity,
localization, and chromatin retention of ATM at DSB sites.
ATM ACTIVATION IN RESPONSE TO CELLULAR STRESS
In addition to DSBs, other types of cellular stress activate ATM in
an Mre11 complex-independent manner (Bakkenist and Kastan,
2003; Guo et al., 2010). The ATM INteracting (ATMIN) protein
(also known as ASCIZ or ZNF822) was identiﬁed as a mediator
of ATM activation in response to hypotonic stress or chloroquine
treatment (Figure 2B; Kanu and Behrens, 2007). ATMIN colo-
calizes to sites of DNA damage with phosphorylated ATM but
deletion of ATMIN does not impair ATM activation or activity fol-
lowing IR treatment. Recentwork fromBehrens and colleagues has
provided compelling evidence that ATMIN and Nbs1 compete for
ATM binding as deletion of either protein enhances ATM signal-
ing through the other (Zhang et al., 2012). Strikingly, they showed
that the deletion of ATMIN rescued the proliferative defects and
premature senescence of Nbs1-deﬁcient cells, suggesting that the
loss of Nbs1 resulted in ATMIN-ATM-mediated activation of
p53 signaling. Murine cells expressing hypomorphic mutants of
Nbs1 that lack the C-terminal ATM interaction domain of Nbs1
(Nbs1ΔC), a candidate domain for competition with ATMIN,
showed normal ATM activation, in conﬂict with cell line com-
plementation and biochemical data (Falck et al., 2005; You et al.,
2005; Diﬁlippantonio et al., 2007; Stracker and Petrini, 2011). One
possibility is thatATMINprovides a redundant function inmurine
cells, where mutant Nbs1 is expressed at physiological levels, that
is obscured by the overexpression of mutant forms of Nbs1 in the
complementation of human cell lines. Amore completemechanis-
tic understanding of how Nbs1 and ATMIN acquire the attention
of ATM and affect its activity will no doubt provide important
insights.
ATM ACTIVATION IN RESPONSE TO REACTIVE OXYGEN SPECIES
Increased ROS has been observed in ATM-deﬁcient tissues and
accumulating evidence suggests that this is highly relevant to A-
T pathology. Recent work from the Paull lab has demonstrated
direct activation of ATM by exposure to ROS in vitro (Guo et al.,
2010). They proposed that ROS activates ATM by promoting
the formation of disulﬁde bridges involving multiple cysteine
residues, including conserved cysteine C2291 in the C-terminal
FATC (FRAP,ATM,TRRAP C-terminal) domain (Figure 2B). The
implications of this mode of activity are very exciting and raise the
possibility that this active form of ATM may engage a different set
of substrates. Again, how this is coordinated with Mre11 complex
orATMIN-dependent activation in the context of complex cellular
stresses will be of great interest and have a potentially high impact
on our understanding of ATM regulation and its role in human
genetic instability disorders.
ATM SUBSTRATES AND CELLULAR FUNCTIONS
As ATM is a kinase, its primary role in the DDR is thought to be
the phosphorylation of proteins that control signal transduction
in response to cellular stresses, such as DSBs and ROS. To date,
roughly 1000 proteins have been identiﬁed as potential ATM
substrates using different approaches (Lavin and Kozlov, 2007;
Matsuoka et al., 2007; Mu et al., 2007; Bensimon et al., 2010; Bhatti
et al., 2011; Choi et al., 2012). While many bona ﬁde ATM targets
have been identiﬁed, someof these can bemodiﬁed by other PIKKs
in response to different stress inputs or if ATM is absent. This over-
lap in substrate speciﬁcity has made connecting a particular PIKK
to speciﬁc targets a formidable challenge in the ﬁeld. Complicating
this is the severe genetic interactions between ATM and DNA-
dependent protein kinase catalytic subunit (DNA-PKcs), making
the propagation of double mutant cells impossible, as well as
the fact that ATR (ATM and Rad3-related) is an essential gene
(Brown and Baltimore, 2000; Sekiguchi et al., 2001; Gladdy et al.,
2006). Large-scale mass spectrometry in combination with kinase
inhibitors has been employed with success and will no doubt be a
useful, though imperfect, approach for future studies to identify
both direct and indirect targets (Bensimon et al., 2010; Choi et al.,
2012). While recent large-scale approaches have broadened the
potential roles of ATM in the DDR, and many functions beyond it,
its well characterized substrates reﬂect important regulatory roles
in cell cycle progression, DNA repair and the control of cell fate,
consistent with the cellular phenotypes of cells lacking ATM.
ATM AND CELL CYCLE CHECKPOINT REGULATION
A primary role of ATM in the DDR is the activation of cell cycle
checkpoints throughout the cell cycle. Defective checkpoint activ-
ities were observed in cells from A-T patients over 20 years ago
and were speculated to be a major contributor to radiosensitivity
(Painter and Young, 1980). Since then, many ATM targets that
are critical for checkpoint activation have been identiﬁed. These
include the tumor suppressor p53, the cohesin subunit SMC1
(structural maintenance of chromosomes proteins), ATF2, the
Mre11 complex and additional enzymes involved in the activation
of the related ATR kinase and checkpoint kinase 1 (Chk1) through
the generation of single-stranded DNA (ssDNA) tails (Shiotani
and Zou, 2009; Stracker and Petrini, 2011).
THE G1/S CHECKPOINT
Cells that experience DNA damage in G1 are prevented from
entering S-phase by the G1/S checkpoint that is dependent on
the activity of the p53 and has been clearly linked to tumor sup-
pression (Massague, 2004). P53 is one of the ﬁrstATM targets to be
identiﬁed andATM-deﬁcient tissues and cells show a strong defect
in the stabilization of p53 following DNA damage (Siliciano et al.,
1997; Banin et al., 1998; Canman et al., 1998). ATM phosphory-
lates p53 on S15 (S18 in mice) and in conjunction with additional
modiﬁcations, contributes to p53 stability (Chao et al., 2006). The
G1/S checkpoint is impaired in ATM-deﬁcient cells although to a
lesser extent than those lacking p53 where the defect is complete
(Xu et al., 1998).
Both ATM- and p53-deﬁcient mice are prone to lymphomas
that are characterized by complex chromosomal rearrangements
in lymphocytes (Zhu et al., 2002; Deriano et al., 2011). As cells
undergoing programed rearrangements during V(D)J [variable
(V), diversity (D), and the joining (J)] recombination should not
enter S-phase until repair takes place, it is likely that defects in
this checkpoint play a major role in predisposition to lymphoma
(Danska and Guidos, 1997). Consistent with this, mice express-
ing mutant alleles of p53 that are competent for initiating the
G1/S checkpoint have a much longer tumor latency and develop
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a broader spectrum of non-lymphoma type tumors than p53
alone (Liu et al., 2004; Barboza et al., 2006). While this interpre-
tation is attractive based on known data, the generation of mice
expressing a mutant, non-acetylatable form of p53 (p533KR) calls
in to question the relationship between DDR signaling mediated
by ATM and p53 and tumorigenesis. Mice homozygous for the
p533KR allele showed defective G1/S checkpoint responses as well
as impaired apoptosis and senescence in response to DNA damage,
but were not prone to rapid tumorigenesis (Li et al., 2012b).
THE INTRA-S PHASE CHECKPOINT
Cells in S-phase exposed toDNAdamage activate the intra-S phase
checkpoint, leading to a transient reduction in DNA synthesis and
suppression of origin ﬁring. Defects in this checkpoint are char-
acterized by radioresistant DNA synthesis (RDS) that was used
as a diagnostic tool and to identify complementation groups in
A-T prior to the cloning of the ATM gene (Painter, 1981). Later
work showed that RDS was also a feature of cells from NBS and
ATLD patients, implicating the Mre11 complex in this checkpoint
response (Stracker and Petrini, 2011). The intra-S phase check-
point is controlled by parallel pathways that are activated by the
Mre11 complex and ATM and the checkpoint kinases Chk1 and
Chk2 that phosphorylate the CDC25A phosphatase, leading to
the inhibition of CDK2 activity and origin ﬁring (Falck et al.,
2002). Nbs1, the SMC1 component of cohesin and ATF2 have
been identiﬁed as a critical ATM targets in the intra-S checkpoint
response (Kitagawa et al., 2004; Bhoumik et al., 2005; Diﬁlip-
pantonio et al., 2007; Stracker and Petrini, 2011). However, this
checkpoint remains poorly deﬁned at themechanistic level and the
implications of its dysfunction to human health remain unclear, as
intra-S defects do not correlate with any severe pathological out-
comes in animal models (Kitagawa et al., 2004; Diﬁlippantonio
et al., 2007; Stracker and Petrini, 2011; Foster et al., 2012).
THE G2/M CHECKPOINT
ATM plays a critical role in the activation of the G2/M checkpoint
that rapidly prevents G2 cells from entering mitosis after DNA
damage. ATM also prevents cells damaged in other phases of the
cell cycle from accumulating in G2 at later time points (this is also
commonly referred to as the G2/M checkpoint in the literature,
although it is mechanistically and genetically distinct; Xu et al.,
2001, 2002). Hypomorphic mutations in Mre11 complex alleles,
or its depletion by viral proteins, impair ATM activation and the
G2/M checkpoint (Williams et al., 2002; Carson et al., 2003; The-
unissen et al., 2003). This is also true, although to a lesser extent, in
cells with Nbs1 mutations that do not have a pronounced effect on
ATM activation (Williams et al., 2002; Uziel et al., 2003). In addi-
tion, some mutations in the tumor suppressor BRCA1, an ATM
substrate that interacts with the Mre11 complex, impair G2/M
checkpoint arrest (Xu et al., 2001, 2002). The deletion of the check-
point kinase Chk2 in any murine backgrounds with defects in the
G2/M checkpoint, including Chk1 heterozygotes, and particular
Mre11 complex or BRCA1 alleles, results in tumor predisposition,
indicating that the G2/M transition is important for tumor sup-
pression (McPherson et al., 2004; Cao et al., 2006; Stracker et al.,
2008; Niida et al., 2010). Understanding howATMorchestrates the
G2/M transitionwill be important for elucidating its role in disease
etiology andwill potentially uncover additional candidate proteins
involved in oncogenesis (we refer the reader to a recent review
of the G2/M transition for more detailed information; Kousholt
et al., 2012).
ATM SIGNALING IN MITOSIS
Available evidence suggests that there is not a general damage-
induced checkpoint response in mitosis. However, a basal “prim-
ing” response that involves ATM and DNA-PKcs is critical for the
normal tolerance of mitotic DNA damage (Giunta et al., 2010). A
notable exception is in Xenopus where the Costanzo lab identiﬁed
XCEP63 as a target of ATM/ATR following mitotic DNA damage
(Smith et al., 2009). XCEP63 is phosphorylated in an ATM/ATR-
dependent manner leading to its detachment from the centrosome
and impairment of spindle assembly and mitotic progression.
Recently,mutations in humanCEP63were found to underlie auto-
somal recessive primarymicrocephaly (Sir et al., 2011). CEP63was
demonstrated to play a key role in the recruitment of CEP152,
another centrosomal protein implicated in microcephaly, to cen-
trosomes and the artiﬁcial tethering of CEP152 to centrosomes
rescued many of the cellular phenotypes of CEP63 mutant cells
(Kalay et al., 2011; Sir et al., 2011). Whether the loss of a mitotic
DDR, centrosome assembly, or additional functions of CEP63
underlie CNSpathology in humans remains to be determined. The
relationship between CEP63 and ATM will require further explo-
ration as the ATM/ATR target site in XCEP63 is not conserved
in higher mammals, although additional ATM/ATR consensus
SQ/TQ sites have been identiﬁed by mass spectrometry.
In addition to regulating the mitotic DDR, ATM has recently
been implicated in the regulation of the spindle assembly check-
point (SAC) through interactions with the Aurora B kinase (Yang
et al., 2011). In the absence of DNA damage, ATM was activated
in mitosis by Aurora B through the phosphorylation of serine
1403 on ATM. The complementation of ATM-deﬁcient cell cul-
tures with S1403A mutants failed to restore the SAC in contrast
to S1981A or wild type ATM expression. While the range of sub-
strates targeted by ATM in mitosis has not been elucidated, the
phosphorylation of the Bub1 kinase, a critical regulator of the
SAC, by ATM appears to play a major role in ATM-mediated
SAC activation. How Aurora B phosphorylation of ATM can initi-
ate its DNA damage-independent activation remains unclear but
will be important to understand with regards to the basic mecha-
nisms of ATM activation as well as the role of ATM in promoting
chromosome stability.
REGULATION OF DNA REPAIR AND TRANSCRIPTION IN THE
CONTEXT OF CHROMATIN
Although much conﬂicting data has been reported, recent work
has clearly deﬁned multiple roles for ATM activity in regulating
both major pathways of DNA repair (NHEJ and HDR) as well as
transcription in the vicinity of sites of DNA damage through its
activity on numerous chromatin substrates.
DNA RESECTION COORDINATES THE CELL CYCLE CHECKPOINT AND
DNA REPAIR
A key feature of the intra-S and G2 checkpoint responses is the
ATM-dependent activation of the ATR and Chk1 kinases through
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the generation of ssDNA by DNA resection (Shiotani and Zou,
2009). Resection is the conversion of a double-stranded DNA
(dsDNA) end to a ssDNA overhang by the nucleolytic removal
of one strand in the 5′–3′ direction. The generation of these over-
hangs is critical for both checkpoint activation and subsequent
HDR-mediated repair. Recent work has elucidated a two-step
model for DNA-end resection following Mre11 complex end cap-
ture (Mimitou and Symington, 2008; Zhu et al., 2008). In the
ﬁrst step, the Mre11 complex and the associated CtIP protein
(Sae2/Ctp1 in yeast) initiate limited 5′–3′ resection of the break
ends. The identity of the nuclease activity (or more likely, activi-
ties) that catalyze this initial step of resection remains an essential
question. Recent work from the Neale laboratory provided evi-
dence that in the context of ends with protein blocked termini,
Mre11 uses its endonuclease activity to nick the DNA and this
is followed by exonucleolytic resection toward the end in a 3′–5′
direction, consistent with the polarity of Mre11 activity (Neale
et al., 2005). In concert, exonuclease 1 (Exo1) could act on the
same strand in the opposite direction consistent with its 5′–3′
polarity. This elegant bidirectional resection model may be gener-
ally applicable toDSB resection, although it is likely that signiﬁcant
redundancy exists, as Mre11 nuclease mutants have mild defects
in resection in yeast and a normal G2/M checkpoint in murine
cells (Buis et al., 2008; Mimitou and Symington, 2009).
In a second step, additional nucleases, such as Exo1 or
DNA2, carry out processive 5′–3′ resection resulting in longer
single-stranded tails. These ssDNA tails are bound by replication
protein-A (RPA) and serve as a platform to recruit replication
factor C (RFC)2–5, the 9–1–1 complex (Rad9, Hus1, Rad1),
TOPBP1 and ATRIP that together facilitate the activation of the
ATR and Chk1 kinases (Cimprich and Cortez, 2008). In addi-
tion to RPA, the single-stranded binding protein complexes SOSS1
and SOSS2 have been implicated in the recruitment of the Mre11
complex, ATM activation and resection via Exo1 (Richard et al.,
2008, 2011a,b; Huang et al., 2009; Yang et al., 2012). However, the
deletion or depletion of the crucial SOSS1 or SOSS2 components
(Obfc2b/SSB1 orObfc2a/SSB2) inmice does not recapitulate these
phenotypes suggesting that theymaybe context or cell type speciﬁc
(Feldhahn et al., 2012).
ATM GOVERNS DNA REPAIR IN HETEROCHROMATIN VIA KAP1
The modulation of chromatin structure is important for DNA
repair processes, including resection, particularly in highly con-
densed regions such as heterochromatin. Recent genome wide
studies have demonstrated that mutations in cancer cells occur
more frequently in heterochromatin, suggesting that their repair
poses a particular challenge to the cell that is relevant to tumori-
genesis (Schuster-Bockler and Lehner, 2012). ATM facilitates
the relaxation of heterochromatin through phosphorylation of
the KAP1 (also known as TIFβ/FRIP1/TRIM28) protein (Ziv
et al., 2006; Goodarzi et al., 2008). Depletion of KAP1 by short
hairpin RNA (shRNA) rescued the radiosensitivity of lines
treated with ATM inhibitor and the complementation of these
lines by a non-phosphorylatable KAP1 mutant caused a repair
defect, even when ATM was not inhibited. These and other
results suggest that the relaxation of chromatin via Kap1 is
a major pathway by which ATM regulates radiosensitivity and
repair in heterochromatin (the role of ATM and KAP1 in hete-
rochromatin is discussed in detail in a recent review (Goodarzi
and Jeggo, 2012)).
REGULATION OF DSB REPAIR THROUGH RNF20
ATM targets numerous ubiquitin ligases to coordinate tran-
scription and repair following DNA damage. The Shiloh and
Komatsu groups both identiﬁed the RNF20–RNF40 heterodimer,
which normally monoubiquitylates H2B to promote transcrip-
tion, as an ATM target required for DNA repair through both
the HDR and NHEJ pathways (Moyal et al., 2011; Nakamura
et al., 2011). The depletion of RNF20 resulted in radiosensitivity
and aberrant localization of numerous DDR proteins, includ-
ing XRCC4, Ku80, and Rad51, which could not be rescued by
a non-ubiquitylatable H2B mutant. Monoubiquitylation of H2B
is known to occur during transcription where it is followed by
the methylation of histone H3K4 and H4K79, the former being
required for the recruitment of the SNF2 (sucrose non-fermenting
2) chromatin remodeling protein. While the reports differ in
their approaches and assessment of methylation following DNA
damage, it was demonstrated using ChIP, under conditions that
favored HDR, that H3K4 methylation and SNF2h (sucrose non-
fermenting 2 homolog) recruitment occurred at break sites in an
RNF20-dependent manner and that the small interfering RNA
(siRNA) depletion of RNF20 and SNF2h was epistatic (Nakamura
et al., 2011). Collectively, these works have led to the proposi-
tion that the ATM-dependent DDR reappropriates the cellular
transcriptional apparatus to sites of DNA damage in order to pro-
mote chromatin remodeling and facilitate repair through multiple
pathways (for a more elaborated perspective on this work we rec-
ommend to the reader a recent review from the Shiloh group;
Shiloh et al., 2011).
ATM REGULATES RNAPI- AND RNAPII-DEPENDENT TRANSCRIPTION
Additional links between ATM, the ubiquitylation machinery and
transcription was established by Greenberg and colleagues using
a novel chromosomal reporter system. They showed that RNA
polymerase II (RNAPII)-dependent transcription is silenced in
kilobase regions surrounding DSBs (Shanbhag et al., 2010). Tran-
scriptional silencing required ATM activity and was partially
dependent upon the H2A ubiquitin ligases RNF8 and RNF168
that have been previously implicated inATM-mediated chromatin
relaxation (Ziv et al., 2006). While reminiscent of previous work
that demonstrated that ATM inhibits RNA polymerase I (RNAPI)
in a manner dependent upon the Mre11 complex and MDC1,
the effects of ATM on RNAPII inhibition appear to be distinct
(Kruhlak et al., 2007). Themechanistic details and additionalATM
substrates that orchestrate this large-scale regulation of RNAPI
and RNAPII, and the consequences of their dysfunction, will be
important to determine. Notably, mutations in RNF168 under-
lie RIDDLE syndrome that has many overlapping pathological
features with A-T (Stewart et al., 2009).
ATM AND THE REGULATION OF CELL FATE IN RESPONSE TO
STRESS
Apoptosis, or programed cell death, is essential for development,
particularly in the immune system, and represents an important
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mechanism for the clearance of cells with DNA damage. Apoptosis
is triggered in response to a variety of DNA lesions, includ-
ing DSBs, and defective apoptosis is considered a hallmark of
cancer cells (Hanahan and Weinberg, 2011). Apoptosis is also rel-
evant in the context of radio and chemotherapy used for cancer
treatment. Cells in the gastrointestinal (GI) tract and the bone
marrow undergo extensive cell death in response to DNA damage,
potentially causing bone marrow failure and severe GI syndrome.
Apoptosis as a response toDSBs is restricted to particular cell types
and tissues, as most cell types in the adult do not undergo apop-
tosis. The exposure to genotoxic stress or the inability to repair
persistent DNA damage can also lead to cell death through other
mechanisms, such as mitotic catastrophe or necrosis, or the induc-
tion of cellular senescence. ATM plays key roles in regulating these
cell fate decisions following genotoxic stress that can inﬂuence
pathological outcomes.
ATM IN APOPTOSIS
Apoptosis in response to DSBs is regulated by p53 in many tis-
sues, including lymphocytes. Stability of p53 is regulated through
its phosphorylation by ATM and Chk2 as well as their regulation
of ubiquitin ligases that control p53 levels, namely mouse dou-
ble minute 2 (MDM2) and murine double minute X (MDMX)
(Jenkins et al., 2012). The mutation of both ATM and Chk2 tar-
get residues in p53 (p53S18/23 mice) to alanine results in apoptotic
defects despite the fact that p53 is stabilized to normal levels (Chao
et al., 2006). Apoptosis is impaired after DNA damage in both
ATM- and Chk2-deﬁcient cells and ATM–Chk2 double mutants
have a stronger apoptotic defect, comparable to that of p53 null
or p53S18/23 animals (Figure 3; Stracker et al., 2007; Stracker and
Petrini, 2008). Together, these and other data suggested that addi-
tional ATM/Chk2 targets besides p53 were required to regulate
p53 stability and responses. Recent work from the Jones lab has
demonstrated that the phosphorylation of MDM2 by ATM plays
a central role in ATM-mediated p53 stabilization and its response
to DNA damage (Gannon et al., 2012). Mice expressing a non-
phosphorylatable mutant of MDM2 exhibited defects in apoptosis
more severe than that seen in ATM deﬁciency and comparable
to that of p53 null animals. This may suggest that this residue
can be acted upon by other PIKKs in the absence of ATM. ATM-
independent apoptosis in lymphocytes has been shown to require
the DNA-PKcs protein using small molecule inhibitors or siRNA
depletion (Callen et al., 2009). A possible scenario based on avail-
able data is that in the absence of ATM, DNA-PKcs can directly
activate Chk2 and modify MDM2 to promote p53-dependent
apoptosis (Figure 3).
The ability of ATM to activate apoptosis in thymocytes in
response to radiation depends largely on the Mre11 complex.
Mutations in Mre11 that impair ATM activation mimic the defec-
tive apoptosis phenotype of ATM-deﬁcient cells (Stracker et al.,
2008). Mutation of the C-terminal ATM interaction domain of
Nbs1 also impairs ATM-dependent apoptosis without affecting
ATM activation (Diﬁlippantonio et al., 2007; Stracker et al., 2007).
Cells lacking the Nbs1 C-terminus show deﬁcient ATM phospho-
rylation of SMC1 and the proapoptotic BH3 interacting-domain
(BID) protein, but normal p53 phosphorylation and stabiliza-
tion, indicating that this domain controls a subset of ATM targets
FIGURE 3 | ATM controls cellular survival in response to DNA damage
through multiple pathways. DNA damage activates apoptosis in a
p53-dependent manner in some cell types such as lymphocytes. p53 is
activated by parallel pathways controlled by the Mre11 complex and ATM
(black arrows) or DNA-PK and Chk2 (red arrows). The Mre11 complex is
required for ATM activation and plays downstream roles mediating access
to targets such as BID. Chk2 can act independently of ATM and may be a
target of DNA-PK that is required for ATM-independent p53-dependent
apoptosis. MDM2 phosphorylation by ATM is required for p53 stability and
activity. ATM is also required for the Chk1 sensitized cell death pathway.
ATM phosphorylates p53-induced protein with a death domain (PIDD)
when Chk1 is inhibited favoring RIP associated Ich-1/CED homologous
protein with death domain (RAIDD) binding that promotes caspase 2
activation and cell death. Murine alleles or small molecules (Chk1 or
DNA-PKcs inhibitors) that affect these pathways are noted in italics. ATM
targets are indicated with a red P.
(Kamer et al., 2005). How the C-terminus of Nbs1 inﬂuences
ATM-dependent apoptosis remains unclear. As p53 is both phos-
phorylated (S18) and stabilized properly, it suggests that MDM2 is
efﬁciently phosphorylated and that ATM can access p53 (Gan-
non et al., 2012). Nbs1 may be required for another critical
modiﬁcation of p53, such as acetylation, or the defect could be
kinetic, caused by inefﬁcient regulation of mitochondrial BID or
another ATM substrate that is yet to be identiﬁed (Li et al., 2012b;
Maryanovich et al., 2012).
Recent work has further elucidated the signiﬁcance of ATM-
mediated BID phosphorylation on cell fate and stem cell mainte-
nance in the bone marrow. Previously, ATM has been implicated
in regulating the self-renewal of hematopoietic stem cells (HSCs).
ATM-deﬁcient mice that escape lymphoma development exhib-
ited progressive bonemarrow failure thatwas rescued by treatment
with antioxidants or the inhibition of p38 mitogen-activated pro-
tein kinase (p38MAPKs; Ito et al., 2004, 2006). Recent work from
the Gross laboratory has identiﬁed BID as an ATM substrate and
a regulator of HSC homeostasis (Kamer et al., 2005; Zinkel et al.,
2005; Maryanovich et al., 2012). Mice expressing a mutant form of
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BID (BIDAA) that is notmodiﬁable byATMwere sensitive to radia-
tion and showed impaired bone marrow regeneration. HSCs from
these mice were less quiescent, exhibited higher levels of ROS and
had increased levels of BID localized to the mitochondria. These
results provide exciting links between the ability of ATM to regu-
late crosstalk between DNA damage, oxidative stress, and the HSC
compartment (Maryanovich et al., 2012). It will also be interesting
to determine if the Mre11 complex, that is required for efﬁcient
IR-induced BID phosphorylation, plays a role in BID-mediated
HSC maintenance (Stracker et al., 2007).
As p53 is mutated in a high percentage of cancers, it is of thera-
peutic interest to identify p53-independent pathways of cell death
that can be exploited to improve the efﬁcacy of cancer treatments.
Using zebraﬁsh and mammalian cells, the“Chk1 suppressed” (CS)
pathway of apoptosis was identiﬁed. Inhibition or depletion of
Chk1 renders p53-deﬁcient cells competent to induce cell death
after DNA damage in an ATM/ATR and caspase 2 (CASP2)-
dependent manner (Chen et al., 2009). Recent work from Sidi
and colleagues has identiﬁed PIDD as an ATM target and criti-
cal component of this alternative cell death pathway (Ando et al.,
2012). ATM modiﬁcation of the PIDD death domain promotes its
binding to RAIDD, rather than the prosurvival RIP1, to activate
CASP2 and cell death (Figure 3). The physiological signiﬁcance of
this pathway, as well as the mechanism by which Chk1 prevents its
activation, remain unclear but it will be of interest to further delin-
eate these pathways as Chk1 inhibition in p53-deﬁcient tumors is
a promising strategy in clinical chemotherapy (Ma et al., 2012;
Origanti et al., 2012).
ATM IN SENESCENCE
In addition to its role in cell death pathways, ATM has also
been implicated in the regulation of senescence, although its
role remains controversial. ATM-deﬁcient ﬁbroblasts in culture
undergo senescence rapidly, likely due in part to the high lev-
els of atmospheric oxygen used in standard culture conditions,
as treatment with antioxidants or normoxic conditions prevent
premature arrest (Parrinello et al., 2003; Ito et al., 2007; Wood-
bine et al., 2011). Thus, ATM inhibits senescence in response
to oxidative stress. On the other hand, senescence induced by
the overexpression of some oncogenes is dependent upon ATM
(Bartkova et al., 2006; Mallette et al., 2007; Efeyan et al., 2009).
As senescence has emerged as an important mechanism of tumor
suppression and aging, it will be critical to clarify the importance
of ATM in different contexts (Campisi, 2012). Recent work has
elucidated a complex relationship between ATM signaling and the
nuclear factor kappa B (NF-κB) and p38MAPK pathways that can
regulate cell survival, promote inﬂammation, and govern cellu-
lar senescence in response to DNA damage, ROS, and oncogene
expression.
A consequence of senescence is the senescence-associated secre-
tory phenotype (SASP) that can provoke defects in differentiation
and promote tumor growth and invasion through the secretion
of growth factors and inﬂammatory cytokines. DNA damage acti-
vates a SASP in primary ﬁbroblasts that is dependent upon ATM,
Nbs1, and Chk2 (Rodier et al., 2009). ATM regulates a subset of
the SASP including IL-6 and IL-8. The Campisi group has demon-
strated that the inhibition of the p38MAPK pathway blocks the
SASP following DNA damage independently of ATM and Nbs1
(Freund et al., 2011). Activity of p38MAPK activity is observed
later than the initial DDR and is restrained by p53, suggesting that
an attenuation of ATM and Chk2 pathways may be a prerequi-
site. Overexpression of a constitutively active p38MAPK activator
MKK6 (MKK6EE) activated a SASP, demonstrating that high lev-
els of active p38MAPK was sufﬁcient. However, DNA damage
induction was also required for optimal induction with several
experimental systems that do not induce p38MAPK activation as
strongly. The activation of the NF-κB pathway was required for
SASP induction downstream of p38MAPK and the authors have
proposed that the DDR and p38MAPKs may co-regulate NF-κB
post-translationally to regulate the expression of its target genes
and the SASP.
The NF-κB pathway is activated in an ATM-dependent manner
in response to some types of DNA damage (Wu et al., 2006). ATM
phosphorylates the NF-κB essential modulator (NEMO), leading
to its ubiquitylation and the export of NEMO and ATM to the
cytoplasm. NF-κB signaling by ATM has been linked to immune
system development, DNA repair, tumor progression, and defects
in the nuclear lamina (Bredemeyer et al., 2008; Barascu et al., 2012;
McCool and Miyamoto, 2012; Osorio et al., 2012). Work from the
Lopez-Otin group recently describedNF-κBactivation in anATM-
and NEMO-dependent manner in mice lacking the metallopro-
teinase Zmpste24 that processes prelamin A to lamin A (Osorio
et al., 2012). This response underlies the progeroid features of mice
lacking Zmpste24 that can be partially rescued by decreasing the
gene dosage of lamin A.
Additional links between ATM and the nuclear lamina were
uncovered by the Bertrand laboratory that found lamin B pro-
tein, but not mRNA, is overexpressed in ATM-deﬁcient cells,
leading to morphological defects (Barascu et al., 2012). Lamin
B stabilization was dependent upon oxidative stress and a func-
tional p38MAPK pathway. The mechanism by which ROS and
p38MAPK promote lamin B stabilization remains unclear but
impaired proteasome-mediated protein degradation caused by
elevated expression of an ubiquitin-like protein ISG15 in the
brain of A-T patients, as well as in ATM-deﬁcient mice has been
reported (Wood et al., 2011). ISG15 counteracts Ub-dependent
proteasome degradation, and thus could provide a mechanistic
explanation for the stabilization of proteins such as lamin B, as it
targets many cytoskeletal proteins including lamin A (Zhao et al.,
2005). How defects in the integrity of the nuclear lamina activate
ATM remains unclear but as the lamin B receptor (LBR) has been
linked to heterochromatin organization in the nucleus, and lamin
B loss is a biomarker of senescence, understanding these connec-
tions will no doubt be informative (Goldberg et al., 1999; Freund
et al., 2012).
ATM AND ONCOGENE-INDUCED STRESS
The overexpression of some oncogenes, such as c-Myc, can cause
replicative stress, leading to an active DDR and the initiation of
apoptosis or senescence depending on the cellular background.
In the case of c-Myc, ATM and p53 have been identiﬁed as cen-
tral mediators of c-Myc signaling (Campaner and Amati, 2012).
Loss of ATM accelerates c-Myc-induced tumorigenesis in both an
epithelial tumor (K5-myc) and lymphoma model (Eμ-myc) in
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part by reducing apoptosis and augmenting proliferation (Pusap-
ati et al., 2006; Maclean et al., 2007). Although it was not assayed
as an endpoint in many previous studies, separation of function
mutations in p53 implicate senescence as a major barrier to c-
Myc-induced tumorigenesis in lymphocytes (Post et al., 2010).
Consistent with this, deletion of the WIP1 phosphatase that
restrains ATM and p53 activity, as well as both the NF-κB and
p38MAPK pathways, delays Eμ-myc-induced tumorigenesis in a
manner that requires both p53 and ATM (Bulavin et al., 2004;
Shreeram et al., 2006a,b; Demidov et al., 2007; Chew et al., 2009).
In contrast to the augmentation of c-Myc driven tumorigenesis
in mice lacking ATM or p53, the mutation or inhibition of ATR
leads to the converse outcome of impaired tumor development
(Murga et al., 2011). These results highlight the inherent differ-
ences in the cellular roles of the ATM and ATR signaling pathways
and have suggested that ATR pathway inhibition has potential as
a chemotherapeutic strategy, particularly in oncogene addicted
tumors (Toledo et al., 2011; Schoppy et al., 2012).
The inﬂuence of ATM deﬁciency on c-Myc-induced tumorige-
nesis is no doubt complex and involves multiple ATM targets. One
target that may be of particular interest is the ubiquitin-speciﬁc
protease 28 (USP28) that was identiﬁed as an ATM/ATR target
through its interactions with 53BP1 and independently through a
screen for genes required for Myc-induced transformation (Zhang
et al., 2006; Popov et al., 2007b). USP28 has also been implicated
in Chk2-dependent apoptosis as well as the maintenance of the
ATM-dependent G2 checkpoint through the ability to stabilize the
claspin protein (Bassermann et al., 2008). Based on these and other
data, it has been proposed that DDR-induced phosphorylation
of USP28 leads to its dissociation from the Fbw7 ubiquitin ligase
complex, allowinguncheckedMycdegradation, and its subsequent
association with DDR components, such as 53BP1, claspin, Nbs1,
andChk2, to promote their stabilization (Popov et al., 2007a). This
model predicts that mice or human patients lacking USP28 would
fail to coordinate Myc levels with DNA damage signaling, poten-
tially causing replication stress and enhanced genomic instability
that could contribute to cancer (Shah et al., 2009).
DIVERSE ROLES OF ATM IN IMMUNITY
Ataxia-telangiectasia patients are more susceptible to infections
and this has been attributed in part to varying degrees of immun-
odeﬁciency. Work in mice- and cell-based systems has identiﬁed a
number of important roles for ATM in both adaptive and innate
immunity, as well as inﬂammatory responses, that may underlie
many aspects of pathology in A-T.
ADAPTIVE IMMUNITY
ATM plays an important role in the development of both T and
B cells and A-T patients often exhibit abnormal T and B lym-
phocyte counts and deﬁcient antibody responses. Lymphocytes
are the main cellular component of the adaptive immune sys-
tem that counteracts infections and cell abnormalities, including
cancer. To react to a wide range of antigens, lymphocytes gener-
ate a diverse repertoire of antigen-speciﬁc receptors that depend
on programed chromosomal rearrangements that are initiated
by enzymes that introduce DNA breaks. These processes, V(D)J
recombination (T and B lymphocytes) and class switch recom-
bination (CSR, in B lymphocytes), are both dependent on intact
ATM function. AsA-T patients are prone to lymphomas, it is likely
that the ability of ATM to monitor the development of lympho-
cytes through the regulation of both DNA repair and apoptosis
plays a critical role in tumor suppression (Nussenzweig and
Nussenzweig, 2010).
The lymphoid organs of mice lacking ATM are structurally
intact but the absolute numbers of thymocytes are reduced due
to developmental defects. The thymocyte population in ATM
null mice is characterized by a reduction in mature single pos-
itive CD4 or CD8 T cells and an increase in immature double
positive thymocytes (Barlow et al., 1996; Xu et al., 1996). Nor-
mal numbers of B cells are present in the spleen but a reduction
in the number of B220+IgM− Pre-B cells was observed in the
bone marrow. Moreover, B cells are unable to respond properly to
stimuli due to defects in B cell homeostasis and the regulation of
programed rearrangements during V(D)J and CSR. Recent work
supporting this has demonstrated that ATM-deﬁcient animals are
able to stimulate T and B cell responses in response to chronic
gammaherpesvirus infection, but that these responses are defec-
tive and unable to efﬁciently suppress viral replication (Kulinski
et al., 2012).
V(D)J RECOMBINATION
During the development of T and B lymphocytes, V(D)J recom-
bination is required for the assembly of antigen receptor genes.
The recombination activating genes 1 and 2 (RAG1 and RAG2)
constitute the RAG recombinase that generates DNA DSBs to
catalyze recombination between the variable (V), diversity (D),
and the joining (J) gene fragments in order to deﬁne the bind-
ing properties of the receptor (Boboila et al., 2012). NHEJ, one of
the two major DSB repair pathways, is critical for the repair of
RAG-induced breaks. The so-called “classical” or C-NHEJ path-
way is deﬁned as theDNA-PKholoenzyme (Ku70/80,DNA-PKcs),
XRCC4, Lig4, Artemis, and XLF. The C-NHEJ pathway repairs the
hairpin capped coding ends (CEs) and the blunt signal ends (SEs)
generated by RAG activity. The kinase activity of DNA-PKcs stim-
ulates the activity of the Artemis endonuclease that is required for
the repair of CEs while the remaining C-NHEJ factors are critical
for repair of both CE and SE ends. Blunt SE ends are repaired
to a large extent in cells lacking DNA-PKcs or Artemis but not
completely to normal levels (Boboila et al., 2012).
ATM colocalizes with RAG at endogenous recombination loci
and RAG-induced DNA breaks persist in ATM-deﬁcient cells due
to incomplete defects in CE repair (Perkins et al., 2002; Callen
et al., 2007; Nakamura et al., 2011). Persistent breaks in the
immunoglobulin heavy chain (IgH) locus promote translocations,
including those with Myc, that are known to promote lymphoma-
genesis and occur at higher rates in ATM-deﬁcient cells (Ramiro
et al., 2006). Recent work from the Alt lab has revealed an unex-
pected redundancy between ATM and other end-joining factors
in the repair of both CE and SEs. Cells lacking both DNA-PKcs
and ATM activity show a strong reduction in the level of SE repair
(Zha et al., 2011b) and mice lacking both XLF and ATM exhibit
reduced SE and CE joining (Zha et al., 2011a). Collectively, these
and other studies suggest that ATM plays a role in monitoring
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C-NHEJ-mediated repair duringV(D)J recombination. This likely
occurs through multiple activities that include the promotion of
RAG complex stability, the activation of checkpoints to prevent the
propagation of persistent breaks, the control of DNA end usage
and the regulation of target proteins, such as H2AX and Artemis,
that are shared with DNA-PKcs (Danska and Guidos, 1997; Bre-
demeyer et al., 2006; Callen et al., 2007; Bennardo and Stark, 2010;
Deriano et al., 2011; Zha et al., 2011a).
CLASS SWITCH RECOMBINATION
In response to cytokine secretion or infections, B cells initiate
antibody class switching (Boboila et al., 2012). This stimulation
leads to rearrangements of the switch regions, thus altering the
effector function of the antibody. Class switching is catalyzed by
the activation-induced deaminase (AID) that promotes strand
breakage. Human A-T patients frequently have impaired devel-
opment of the immunoglobulin subtypes IgA, IgG2, IgG4, and
IgE in the serum and ATM-deﬁcient mice show strong defects
in CSR (Lahdesmaki et al., 2000; Pan et al., 2002; Lumsden et al.,
2004; Reina-San-Martin et al., 2004). In contrast, AID-dependent
somatic hypermutation is not strongly affected by ATM deﬁciency
(Pan-Hammarstrom et al., 2003; Lumsden et al., 2004).
Class switch recombination depends on the core C-NHEJ
machinery but also has distinct requirements from V(D)J. The
mechanism by which ATM regulates CSR is likely complex and
represents a composite of the misregulation of many substrates.
The ATM substrate 53BP1 is critical for both V(D)J and CSR
where it has been proposed to play multiple roles including the
synapsis of distal ends and the protection of free ends from
DNA resection (Diﬁlippantonio et al., 2008; Dimitrova et al., 2008;
Bothmer et al., 2010; Bunting et al., 2010). The localization of
53BP1 toDNAbreaks is dependent onH4K20methylation and the
PIKK-dependent phosphorylation of H2AX (Celeste et al., 2003;
Bothmer et al., 2011). 53BP1 is phosphorylated on 28 consen-
sus PIKK SQ/TQ target sites and the mutation of all of these
residues to alanine impairs the ability of 53BP1 to support CSR
andblock resection, but does not prevent its localization to γH2AX
containing breaks (Bothmer et al., 2011).
Recent work from the de Lange and Nussenzweig laborato-
ries has shed light on the relevance of 53BP1 phosphorylation
by ATM as they have demonstrated the PIKK consensus sites are
required for its interactions with the RIF1 protein and the reg-
ulation of DNA resection (Jankovic et al., 2013; Zimmermann
et al., 2013). In lymphocytes, the interaction between 53BP1
and RIF1 is ATM-dependent and the deletion of RIF1 leads to
increased AID-dependent breaks in the IgH locus, an accumula-
tion of cells in G2/M and extensive 5′–3′ resection. The Casellas
and Nussenzweig labs have linked the aberrant resection of AID-
induced breaks in the absence of 53BP1 to lymphomagenesis
using an innovative high-throughput sequencing approach that
mapped AID-induced translocations as well as the asymmetric
binding of the ssDNA binding protein RPA, allowing them to
monitor resection (Jankovic et al., 2013). Further work will be
required to understand precisely how ATM-deﬁcient cells bypass
the severe phenotypes of RIF1 and 53BP1 mutants in CSR, poten-
tially through the redundant functions of other PIKK activities
such as DNA-PKcs.
ATM IN FERTILITY
Due to the young age of A-T patients, fertility is often overlooked
as a clinical issue. However, ATM plays critical roles in germline
development as A-T patients present with gonadal dysgenesis and
both male and female mice lackingATM are infertile due to defects
in meiotic progression (Barlow et al., 1996). Meiosis is the special
cell division that ensures the formation of haploid cells, sperma-
tozoa and ova, from diploid progenitor germ cells. Germ cells
undergo two rounds of chromosome segregations after replicating
their genomes only once. During the ﬁrst meiotic division, DSBs
are generated by the SPO11 protein and repaired by homologous
recombination (HR; Keeney et al., 1997). HR leads to the synapsis
of homologous chromosomes that are stabilized by the synaptone-
mal complex (SC), formed by the union of the two chromosomal
core axes by a central element. Repair of DSBs inmeiosis can lead to
the formation of non-crossovers (NCO,when a small region of the
homologous chromosome is used as template to repair the dam-
age) or crossovers (CO, when ﬂanking regions around the DSBs
are exchanged between the homologs). The formation of the right
number of COs is critical to properly segregate the homologs in
the ﬁrst meiotic division and reduce the genome by half. In fact,
inaccurate CO distribution in human oocytes is believed to be the
major cause of human aneuploidy (Nagaoka et al., 2012).
ATM has a crucial role in the completion of mouse gametoge-
nesis since both male and female ATM-deﬁcient mice are sterile
(Barlow et al., 1996). Testes and ovaries from ATM null animals
display massive germ cell loss. While ATM−/− spermatocytes
arrest at the pachytene stage of meiotic prophase,ATM−/− females
lose all oocytes during the ﬁrst days of life, before completing mei-
otic prophase (Barlow et al., 1998; Hamer et al., 2004; Di Giacomo
et al., 2005). The cytological analysis of ATM−/− spermatocytes
revealed that ATM is required to complete homologous chromo-
some synapsis (Barlow et al., 1998; Pandita et al., 1999). SCs in
ATM mutant spermatocytes are fragmented and this is dependent
on DSB formation, as Spo11−/− ATM−/− spermatocytes do not
show broken SCs (Bellani et al., 2005). Moreover, the ends of the
fragmented axes from ATM−/− spermatocytes contain recombi-
nation markers such as γH2AX, RPA, or RAD51 (Plug et al., 1997;
Barchi et al., 2008).
As expected from the presence of these synaptic defects, recom-
bination is compromised in ATM−/− spermatocytes. H2AX
phosphorylation, that arises as a response to programed DSB
formation in early meiotic prophase, is delayed, implying that
ATM is involved in the early steps of meiotic recombination
(Fernandez-Capetillo et al., 2003; Barchi et al., 2005; Turner et al.,
2005). Accordingly, the assembly of RAD51 foci is inefﬁcient and
mislocalized in ATM−/− spermatocytes. While RAD51 foci colo-
calize with the SC in wild type cells, multiple foci also form in the
chromatin of ATM mutant cells (Barlow et al., 1997, 1998).
The gonadal pathology of ATM−/− mice is strongly inﬂuenced
by the failure to complete meiotic recombination as it is partially
rescued by the heterozygosity of Spo11 that reduces DSB forma-
tion to 70–85% of wild type levels (Bellani et al., 2005; Barchi
et al., 2008; Cole et al., 2012). In this background, ATM−/− sper-
matocytes are able to complete meiotic prophase. Nevertheless,
Spo11+/− ATM−/− spermatocytes are unable to complete mei-
otic recombination because markers of unrepaired breaks, like
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phosphorylated H2AX, can be found even in cells that have com-
pleted meiotic prophase (Barchi et al., 2008). The persistence of
DSBs or recombination intermediates normally provokes a check-
point response that delays or stops meiotic progression, and can in
some cases initiate programed cell death (MacQueen andHochwa-
gen, 2011). In mice, DSB-dependent arrest in meiosis is believed
to occur at the pachytene stage of meiotic prophase I (de Rooij
and de Boer, 2003). However, despite exhibiting multiple unre-
paired DSBs, Spo11+/− ATM−/− spermatocytes do not arrest
at pachynema and progress to metaphase I (Bellani et al., 2005;
Barchi et al., 2008). This uncoupling of DSB repair and mei-
otic prophase progression suggests that ATM could be required
as part of a checkpoint mechanism that controls meiotic devel-
opment in the mouse, a possibility that remains to be formally
tested.
Heterozygosity of Spo11 has also revealed that ATM is involved
in CO control, as Spo11+/− ATM−/− cells have more COs
than wild type cells (Barchi et al., 2008). Interestingly, Spo11+/−
ATM−/− spermatocytes fail to form the obligate CO between the
X and Y chromosomes, that contain a small region of homology
that guarantees their proper segregation at the end of the ﬁrst
meiotic division. Furthermore, COs are more closely positioned
in Spo11+/− ATM−/− mutants than in Spo11+/− spermatocytes,
suggesting that ATM not only is involved in controlling the num-
ber of COs formed, but also in their proper position and spacing,
both crucial aspects for allowing proper homologous chromo-
some segregation. These studies reveal that ATM may have an
important role in coordinating meiotic chromosome dynamics,
including chromosome axis formation as well as recombination
(Barchi et al., 2008). Thus, the tight relationship between SC
defects and inefﬁcient recombination in ATM-deﬁcient cells sug-
gests that ATM could coordinate these two mechanisms to ensure
proper meiotic prophase progression in mouse spermatocytes.
Interestingly, mice with hypomorphic alleles of the Mre11 or
Nbs1 genes exhibited meiotic defects similar to that of Spo11+/−
ATM−/− mice. Mre11ATLD1/ATLD1 or Nbs1ΔB/ΔB spermatocytes
showed aberrant synapsis among homologous chromosomes, per-
sistence of recombination markers until late meiotic prophase and
altered number and location of COs (Cherry et al., 2007). These
ﬁndings suggest that the Mre11 complex participates in meiotic
recombination but more importantly, that most ATM functions
during meiosis may be dependent on the Mre11 complex. Never-
theless, it is worth noting that, unlike Spo11+/− ATM−/− mice,
both Mre11ATLD1/ATLD1 and Nbs1ΔB/ΔB male mice are subfertile.
This may imply that some of the meiotic activities of ATM are
independent of the MRN complex function or that leaky ATM
function in theseMre11 complexmutant backgrounds is sufﬁcient
for some degree of fertility (Theunissen et al., 2003).
Recently, the Jasin and Keeney labs reported that ATM is
involved in controlling the number of meiotic DSBs created by
Spo11 (Lange et al., 2011). Detecting the DNA oligonucleotides
covalently linked to Spo11 as a readout of DSB formation, they
showed that ATM−/− mice have up to 10-fold more DSBs than
wild type littermates (Neale et al., 2005; Lange et al., 2011). This
was not due to differences in the cellularity of the mutant testis,
as other mutants that arrest at the same stage as ATM−/−, such as
Dmc1−/−, have approximately a 50% reduction in the amount of
Spo11-oligo complexes compared to wild type testis. They also
showed that DSB formation was dependent on Spo11 expres-
sion since Spo11+/− ATM−/− had fewer DSBs than ATM−/−
spermatocytes, but still signiﬁcantly more than wild type cells.
Moreover, cells expressing two extra copies of the Spo11β in an
ATM−/− background had even more DSBs than ATM−/− sper-
matocytes, something that was not observed in an ATM proﬁcient
background. This work highlights the remarkable control of DSB
formation in meiotic cells, revealing that it may be similarly dele-
terious for a meiocyte to form too few or too many DSBs. The
authors propose that activation of ATM by DSB formation would
create a local negative feedback loop that would inhibit Spo11
activity in the vicinity of a DSB. This mechanism might be impor-
tant to evenly space DSBs along the genome, in order to promote
proper homologous synapsis, as well as minimizing the forma-
tion of DSBs in both sister chromatids in the same region of the
genome, which could impair meiotic recombination.
ATM IN THE DEVELOPMENT OF THE CENTRAL NERVOUS
SYSTEM
For reasons that remain largely unclear, brain development is
highly susceptible to defects in the DDR. Unlike the immune sys-
tem or germline, there are no known programs of DNA breakage
and repair that would provide an obvious trigger for cell death.
It has been speculated that mitochondrial defects, the accumula-
tion of ROS, transposon mobilization, innate immune responses,
the regulation of apoptosis or speciﬁc repair pathway defects may
contribute to triggering neuronal cell death (Coufal et al., 2011;
McKinnon, 2012; Petersen et al., 2012; Valentin-Vega and Kastan,
2012). One of the central pathologies associated with A-T is neu-
rodegeneration, characterized by cerebellar atrophy and the loss of
Purkinje and granule cells and subsequent ataxia. Notably, human
diseaseswith themost similar neuropathology toA-T are causedby
genes involved in the repair of diverse types DNA lesions (for more
information on this topic, as well as the general neuropathology
of A-T, we recommend to the reader this recent review; McKin-
non, 2012). Unfortunately, neurodegeneration remains the most
poorly understood aspect of A-T, as pronounced neurodegenera-
tion and ataxia are not observed in mice lacking ATM. However,
many insights have been gleaned from animal models and other
systems that provide insight into the roles of ATM and the DDR
in the CNS.
Central nervous systempathology is a feature common tomany
diseases caused by mutations in genes that encode members of
the ATM-dependent DDR, including MRE11 (ATLD),NBS1/NBN
(NBS), RAD50 (NBSLD), RBBP8/CtIP (Seckel), ATR (Seckel),
CEP63 (MCPH), PNKP (MCSZ), TDP1 (SCAN1), and ATM (A-
T; Das et al., 2009; Waltes et al., 2009; Segal-Raz et al., 2011; Sir
et al., 2011; Stracker and Petrini, 2011; McKinnon, 2012; Poul-
ton et al., 2012; Reynolds et al., 2012). However, depending on the
particular mutation, patients, and in some cases, animal models,
will develop either microcephaly (deﬁned as a head circumference
two-standard deviations smaller than the average) or neurode-
generation (deﬁned as the progressive loss of neurons). It remains
mechanistically unclear why mutations in MRE11 result in neu-
rodegeneration, similar to what is observed in A-T patients, while
other mutations in NBS1 or RAD50 cause microcephaly.
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Characterization of hypomorphic Nbs1 and Mre11 alleles in
mice has revealed differential inﬂuences on the ATM-dependent
DDR. The Mre11ATLD1 allele impairs ATM activation, thus reduc-
ing the total pool of active ATM and potentially affecting all
substrates (Theunissen et al., 2003). In contrast, the Nbs1ΔB allele
does not impair ATM activation but reduces ATM activity on par-
ticular substrates (e.g., SMC1), while not affecting others (e.g.,
p53; Stracker et al., 2008). One clear phenotypic difference lies in
the ability of these alleles to induce apoptosis following IR treat-
ment (Stracker et al., 2007, 2008). Activation of p53-dependent
apoptosis is impaired in the thymus and GI tract of Mre11ATLD1
animals but is indistinguishable from wild type in Nbs1ΔB. Using
both IR treatment and Lig4 deﬁciency to induce apoptosis in the
developing brain, it has been demonstrated that this difference in
apoptosis proﬁciency also applies to the CNS (Shull et al., 2009).
An attractive possibility proposed from this work is that the status
of apoptosis may dictate whether there is cellular attrition during
development, leading to microcephaly, or whether cells experienc-
ing genotoxic stress survive and are lost later due to other cell death
pathways triggered by genomic instability, causing neurodegenera-
tion. More recently, ATLD patients with microcephaly, rather than
neurodegeneration, have been identiﬁed aswell asNBSLDpatients
with microcephaly due to RAD50 mutations (Waltes et al., 2009;
Matsumoto et al., 2011). Determining if these MRE11 or RAD50
alleles impair apoptosis would provide a means for testing this
proposition. The major question remains as to what triggers the
DDR in the CNS and whether a few common or many diverse
mechanisms are at play in the human diseases.
ATMdeﬁciency is synthetically lethal with both theMre11ATLD1
and Nbs1ΔB alleles, hampering efforts to identify independent
effects or potential redundancies in development (Williams et al.,
2002; Theunissen et al., 2003). Deletion of any of the Mre11
complex members, including Nbs1, is embryonic lethal. Never-
theless, using conditional alleles, it has been demonstrated that
CNS-speciﬁc loss of Nbs1 leads to microcephaly, defects in the
development of the cerebellum and ataxia, in contrast to ATM-
deﬁcient mice or hypomorphic Nbs1 alleles that do not exhibit
ataxia (Kang et al., 2002;Williams et al., 2002; Frappart et al., 2005;
Stracker and Petrini, 2011). Many of these defects were rescued
by loss of p53 and p53 activation was observed in CNS tissues
where Nbs1 was deleted, suggesting that ATM activation may play
a role in the pathological outcomes resulting from Nbs1 deﬁciency
(Frappart et al., 2005). However, in contrast to p53 deﬁciency, loss
of ATM exacerbated the microcephaly and ataxia phenotypes of
CNS-speciﬁc Nbs1 deletion, again conﬁrming that ATM and the
MRN complex make independent contributions to CNS devel-
opment (Dar et al., 2011). In addition, ATM-deﬁcient mice with
a deletion of Nbs1 in the CNS showed impaired growth and a
markedly shortened life span. It would be interesting to compare
theCNSof mice lackingbothNbs1 andATMINasATMINdeletion
elicits neurodegeneration and rescues other cellular phenotypes of
Nbs1 null tissues (Kanu et al., 2010; Zhang et al., 2012). Whether
ATMIN deletion would rescue CNS development by impairing
ATM-mediated p53 activation or enhance the defects, as seen in
mice lacking ATM, would be mechanistically informative.
One explanation invoked for the synthetic lethality of Mre11
complex mutations and ATM deﬁciency is the role of the Mre11
complex in activating ATR (Williams et al., 2002). Loss of ATR is
embryonic lethal and hypomorphic mutations mimicking those
found in human Seckel syndrome result in severe microcephaly
in mice and are synthetically lethal with ATM deﬁciency (Brown
and Baltimore, 2000; Murga et al., 2009; Ragland et al., 2009). The
conditional deletion of ATR in the CNS also causes microcephaly
and defective cerebellar development (Lee et al., 2012). However,
in contrast to the deletion of Nbs1 in the CNS, the resulting
pathology was not dependent on p53 (Murga et al., 2009). The
balance of ATM and ATR signaling in the development of the
CNS, and the organism as a whole, is clearly of great importance
but remains poorly understood. Cleanly separating their func-
tions and accounting for the potential redundancy of DNA-PKcs
signaling remains an important challenge to overcome.
Recent work from the Herrup lab has linked ATM’s role
in CNS development to transcriptional regulation in neurons.
They proposed that transcriptional defects caused by the aber-
rant nuclear localization of HDAC4 in ATM-deﬁcient cells may
contribute to neurodegeneration (Li et al., 2012a). Using a vari-
ety of approaches including ChIPseq, they showed that HDAC4
accumulated in the nucleus in ATM-deﬁcient neurons and caused
global defects in histone acetylation and neuronal gene expression.
Of particular interest, nuclear HDAC4 suppressed the activity of
myocyte enhancer factor 2A (MEF2A) and cAMP-responsive ele-
ment binding protein (CREB) that control prosurvival programs.
Treatment with histone deacetylase inhibitors reduced cell death
and markers of cell cycle reentry in the ATM-deﬁcient cerebellum.
HDAC4 localization does not appear to be regulated directly by
ATM-mediated phosphorylation but instead through ATM activ-
ity on the P65 subunit of PP2A, a known interactor of ATM
(Goodarzi et al., 2004). ATM phosphorylation of PP2A promoted
its cytoplasmic localization and prevented the dephosphoryla-
tion of HDAC4. The injection of mutant HDAC4 that localized
only to the cytoplasm, coupled with shRNA downregulation of
endogenous HDAC4, rescued some of the behavioral defects of
ATM-deﬁcient mice and reduced markers of cell death, providing
a proof of principle for HDAC4 modulation in therapy. HDAC4
is expressed in many areas of the brain as well as other tissues,
thus the pathological speciﬁcity of ATM loss on neurons remains
unclear. It will be important to understand as well how HDAC4
is regulated in similar diseases resulting from Mre11 complex
mutations to understand if this mechanism is particular to A-T
or may have more widespread signiﬁcance in genetic instability
diseases.
THE ROLES OF ATM IN METABOLISM
Ataxia-telangiectasia patients exhibit several indices of metabolic
disease including increased susceptibility to diabetes and impaired
glucose metabolism. Some early indications for molecular roles of
ATM in metabolism came from the identiﬁcation of the transla-
tion regulator 4E-BP1 as an ATM target in response to insulin,
the observation that ROS is increased in ATM-deﬁcient animals
and evidence for the peroxisomal localization of ATM (Barlow
et al., 1999; Watters et al., 1999; Yang and Kastan, 2000; Kamsler
et al., 2001). Subsequently it has been demonstrated that treatment
with antioxidants could delay tumor formation in ATM null mice
and rescue other aspects of development (Ito et al., 2004, 2007;
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Schubert et al., 2004; Reliene and Schiestl, 2006,2007; Reliene et al.,
2008). The recent demonstration that ROS can directly activate
ATM, that ATM can promote antioxidant responses through the
stimulation of the pentose phosphate pathway (PPP) and evidence
thatATMplays a role inmonitoringmitochondrial quality control,
has again pointed toward a central function of ATM in controlling
cellular ROS metabolism (Guo et al., 2010; Cosentino et al., 2011;
Valentin-Vega et al., 2012; these topics will be covered in brief here
but we refer the readers to recent reviews/commentaries that cover
some aspects in greater depth; Alexander et al., 2010b; Ditch and
Paull, 2012; Valentin-Vega and Kastan, 2012).
Autophagy, the catabolism of dysfunctional or excess cellular
components, is induced in response to diverse stresses including
elevated ROS. In response to ROS, cytoplasmic ATM phosphory-
lated liver kinase B1 (LKB1) and activated AMP-activated protein
kinase (AMPK; Alexander et al., 2010a). Together LKB1 and
AMPK activated TSC2 that in turn repressed the mammalian tar-
get of rapamycin complex 1 (mTORC1) and induced autophagy.
Recent work from the Kastan lab has shown that ATM-deﬁcient
thymocytes exhibited increased ROS and mitochondrial mass, as
well as other markers of mitochondrial dysfunction (Valentin-
Vega et al., 2012). Cells from ATM mutant animals have increased
basal autophagy but defects in mitophagy induced by mitochon-
drial membrane decoupling agents. A reduction in autophagy,
by the deletion of one allele of the Beclin1 gene, reverted some
of the mitochondrial phenotypes and signiﬁcantly delayed tumor
suppression without affecting the DDR, providing evidence that
autophagy promotes tumorigenesis in the absence of ATM. In
addition, ATM localized to mitochondrial fractions and was acti-
vated in response to mitochondrial membrane uncoupling. These
and other data have led to the proposal that ATM may directly reg-
ulate mitochondrial homeostasis through responding to ROS or
by regulating mitochondrial quality control genes, such as PINK1
or Parkin (Valentin-Vega and Kastan, 2012). As these proteins are
mutated in Parkinson’s disease, also characterized by CNS degen-
eration, understanding the regulation of mitochondrial integrity
by ATM may shed light on the etiology of neurodegeneration
in A-T.
Mitochondrial dysfunction can lead to excessive ROS gener-
ation that is a phenotype of ATM-deﬁcient cells that has been
described in many experimental settings, including those men-
tioned here in previous sections. Recent work from the Costanzo
lab has deﬁned a role for ATM in activating the PPP in response to
DNA damage (Cosentino et al., 2011). ATM increased the activity
FIGURE 4 | Selected summary of the ATM signaling network. A non-comprehensive schematic of ATM signaling pathways described in the text. ATM
substrates are indicated in bold black, other pathway effectors in black, affected cellular processes in blue, and cell cycle checkpoints in green. See text for
details regarding the signaling pathways depicted.
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of glucose-6-phosphate dehydrogenase (G6PD) by promoting its
interaction with heat shock protein 27 (HSP27). This led to an
increase in the production of nicotinamide adenine dinucleotide
phosphate (NADPH), an essential co-factor for antioxidants and
ribonucleotide reductase, as well as ribose-5-phosphate, that can
be used for nucleotide biosynthesis. Interestingly, HSP27 is an
important downstream target of the p38MAPK pathway and inhi-
bition of p38 activity impaired the ATM-mediated stimulation
of G6PD and phosphorylation of HSP27 on a target site regu-
lated by p38MAPK (Cosentino et al., 2011). This indicated that
p38MAPK activity was stimulated by ATM and required for ATM
to promote an antioxidant defense through the PPP. In contrast,
several reports have implicated p38MAPK activity in phenotypic
outcomes resulting from increased ROS in the absence of ATM,
including lamin B accumulation, impaired HSC homeostasis,
impaired neural stem cell proliferation, cytokine secretion, and
defective neoangiogenesis (Kim and Wong, 2009; Freund et al.,
2011; Barascu et al., 2012; Maryanovich et al., 2012; Okuno et al.,
2012). Understanding the complex relationship between ATM
and p38MAPK signaling pathways will no doubt be of central
importance in elucidating the mechanisms by which ATM mod-
ulates metabolism and suppresses a wide range of pathological
outcomes.
Mice expressing hypomorphic Mre11 complex alleles recapit-
ulate most DDR related aspects of ATM deﬁciency but are not
tumor prone and do not exhibit the same oxygen-dependent phe-
notypes observed in the absence of ATM (Williams et al., 2002;
Theunissen et al., 2003; Ito et al., 2004; Diﬁlippantonio et al., 2005;
Stracker et al., 2007;Valentin-Vega et al., 2012). It is therefore likely,
at least in mice, that ROS signaling via ATM is largely intact and
this could be sufﬁcient for tumor suppression in Mre11 complex
mutants. However, the clinical presentation in human patients of
the same Mre11ATLD1 mutation modeled in mice is very similar
to that of A-T, arguing against this possibility (Stewart et al., 1999;
Theunissen et al., 2003). As so few ATLD patients with any one
MRE11 allele have been identiﬁed, it is difﬁcult to deﬁnitively
compare tumor predisposition, but as mitochondrial dysfunc-
tion and the response to ROS has been implicated as a major
inﬂuence on the disease phenotypes, including neurodegenera-
tion and tumorigenesis, it will be important to understand this
aspect of ATM signaling and to what extent it is inﬂuenced or not
by the Mre11 complex, ATMIN or other regulators or substrates
of ATM.
CONCLUDING REMARKS
Our knowledge of ATM signaling in development and disease is
ever expanding due to the creative work of dozens of labs using
diverse experimental systems (Figure 4). The identiﬁcation of
speciﬁc ATM substrates and their functions will be instrumen-
tal in elucidating the mechanisms by which ATM can control so
many critical cellular processes. This will require innovation at the
level of sensitive high-throughput analysis of phosphorylation,
and other PTMs, as well detailed single gene studies in available
model systems. It is clear that the generation of animal models
has been, and continues to be, invaluable to our understanding of
ATM in tissue-speciﬁc processes such as apoptosis, CNS develop-
ment, immunity, and angiogenesis, but they also do not faithfully
recapitulate many crucial aspects of the human disease. Gene edit-
ing technologies, such as zinc-ﬁnger nucleases, should allow the
manipulation of ATM and associated genes in higher organisms
that may more faithfully recapitulate the human condition, partic-
ularly CNS pathology. Coupled with high-resolution sequencing
and mass spectrometry-based technologies, including metabolic
proﬁling, the pieces of the ATM puzzle will continue to fall into
place and new strategies to exploit this knowledge can be used to
beneﬁt patients.
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